Madrigal Pharmaceuticals (MDGL) Competitors $428.11 -8.00 (-1.83%) As of 02:35 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MDGL vs. BIIB, INCY, NBIX, UTHR, BMRN, EXEL, EXAS, HALO, RGEN, and IONSShould you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Exelixis (EXEL), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), Repligen (RGEN), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Madrigal Pharmaceuticals vs. Its Competitors Biogen Incyte Neurocrine Biosciences United Therapeutics BioMarin Pharmaceutical Exelixis Exact Sciences Halozyme Therapeutics Repligen Ionis Pharmaceuticals Madrigal Pharmaceuticals (NASDAQ:MDGL) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, analyst recommendations, risk, profitability and earnings. Does the media refer more to MDGL or BIIB? In the previous week, Biogen had 28 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 42 mentions for Biogen and 14 mentions for Madrigal Pharmaceuticals. Biogen's average media sentiment score of 1.25 beat Madrigal Pharmaceuticals' score of 1.22 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Madrigal Pharmaceuticals 11 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biogen 28 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in MDGL or BIIB? 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 21.5% of Madrigal Pharmaceuticals shares are owned by insiders. Comparatively, 0.2% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has higher earnings and valuation, MDGL or BIIB? Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMadrigal Pharmaceuticals$515.55M18.44-$465.89M-$12.85-33.32Biogen$10.00B2.09$1.63B$10.4613.61 Is MDGL or BIIB more profitable? Biogen has a net margin of 15.31% compared to Madrigal Pharmaceuticals' net margin of -54.68%. Biogen's return on equity of 13.85% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Madrigal Pharmaceuticals-54.68% -38.38% -27.32% Biogen 15.31%13.85%8.32% Which has more risk & volatility, MDGL or BIIB? Madrigal Pharmaceuticals has a beta of -1.02, indicating that its stock price is 202% less volatile than the S&P 500. Comparatively, Biogen has a beta of 0.11, indicating that its stock price is 89% less volatile than the S&P 500. Do analysts rate MDGL or BIIB? Madrigal Pharmaceuticals currently has a consensus target price of $459.25, indicating a potential upside of 7.27%. Biogen has a consensus target price of $185.74, indicating a potential upside of 30.45%. Given Biogen's higher possible upside, analysts plainly believe Biogen is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Madrigal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.90Biogen 0 Sell rating(s) 21 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.34 SummaryBiogen beats Madrigal Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDGL vs. The Competition Export to ExcelMetricMadrigal PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$9.50B$2.82B$5.73B$9.81BDividend YieldN/A48.51%6.66%4.48%P/E Ratio-33.2922.6982.3826.51Price / Sales18.44699.07526.77107.89Price / CashN/A26.3325.7028.92Price / Book13.666.8110.636.55Net Income-$465.89M$32.94M$3.28B$266.04M7 Day Performance0.72%0.18%-0.35%-0.79%1 Month Performance41.68%7.61%9.99%6.02%1 Year Performance81.10%0.06%48.79%21.97% Madrigal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDGLMadrigal Pharmaceuticals4.1421 of 5 stars$428.11-1.8%$459.25+7.3%+76.5%$9.50B$515.55M-33.2990Positive NewsBIIBBiogen4.9103 of 5 stars$132.22-0.3%$185.74+40.5%-31.8%$19.39B$9.68B12.647,605Trending NewsINCYIncyte4.7099 of 5 stars$84.61+1.1%$81.60-3.6%+30.9%$16.52B$4.24B19.232,617Positive NewsShort Interest ↑NBIXNeurocrine Biosciences4.8627 of 5 stars$139.60+0.5%$159.50+14.3%+11.7%$13.85B$2.36B41.301,800News CoveragePositive NewsShort Interest ↑UTHRUnited Therapeutics4.3912 of 5 stars$304.76-0.8%$382.00+25.3%+11.3%$13.75B$2.88B11.901,305Trending NewsAnalyst ForecastInsider TradeShort Interest ↑BMRNBioMarin Pharmaceutical4.9978 of 5 stars$58.27+1.0%$93.17+59.9%-35.2%$11.19B$2.85B17.293,040Positive NewsAnalyst ForecastEXELExelixis4.8577 of 5 stars$37.42-1.3%$44.06+17.7%+42.8%$10.07B$2.17B17.991,147Analyst RevisionEXASExact Sciences4.8023 of 5 stars$47.42+1.0%$67.05+41.4%-22.2%$8.98B$2.76B-8.737,000Positive NewsShort Interest ↑HALOHalozyme Therapeutics4.6579 of 5 stars$73.15+0.5%$67.11-8.3%+14.9%$8.56B$1.02B16.74390News CoveragePositive NewsInsider TradeRGENRepligen4.8288 of 5 stars$122.32+0.1%$169.45+38.5%-20.0%$6.88B$634.44M-489.261,778News CoveragePositive NewsAnalyst ForecastIONSIonis Pharmaceuticals3.7426 of 5 stars$42.63+0.0%$59.64+39.9%+20.6%$6.80B$705M-23.171,069Trending NewsAnalyst ForecastGap Up Related Companies and Tools Related Companies Biogen Competitors Incyte Competitors Neurocrine Biosciences Competitors United Therapeutics Competitors BioMarin Pharmaceutical Competitors Exelixis Competitors Exact Sciences Competitors Halozyme Therapeutics Competitors Repligen Competitors Ionis Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDGL) was last updated on 9/3/2025 by MarketBeat.com Staff From Our PartnersHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe $365M annual revenue crypto play While Bitcoin generates zero operational revenue, one DeFi protocol qu...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
